An interventional study of Kandoo in Depression Disorders, sponsored by Child Mind Institute. Not yet recruiting at 1 site in United States. Open to participants aged 13 Years to 25 Years. Per ClinicalTrials.gov, last updated 2025-02-13.
Sponsored by Child Mind Institute · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,715 studies in Depression with a site in United States — 582 open to participants now, 720 under way, 30 of them phase 3. Depression · United States.
Among the 3,715 studies in Depression with a site in United States, this one is the 804th largest by planned enrollment of the 3,322 interventional ones that give a count, is one of 208 that started in 2025, is one of 2,221 with no phase, reaches primary completion later than 56 of the 718 other live ones, and was the 3,397th registered.
8,595 studies on the registry are indexed under Depression; 1,732 are open to participants now.
Browse Depression studies →582 of the 3,715 studies in Depression with a site in United States are open now. Recruiting first, the newest first:
Medical University of South Carolina · Sites in United States
Ages 18–70
Children's Mercy Hospital Kansas City · Sites in United States
Ages 13–17
NeuroRx, Inc. · Sites in United States
Ages 18–80
University of Michigan · Sites in United States
Ages 13+ · Healthy volunteers
Ohio State University · Sites in United States
Ages 21–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1,094 Depression studies recruiting now, 472 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 314 take healthy volunteers.
This study: 13 Years to 25 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,715 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 235 · Phase 2 441 · Phase 3 285 · Phase 4 265
First in 1977; this study’s year is marked. 208 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 81 across 7,078 interventional studies indexed under Depression.
Median enrollment 72 across the 3,322 interventional studies, 138 across the 371 observational. Of the 2,764 that completed or were terminated, 1,045 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
392 of 3,715 have an industry lead sponsor. The 10 most frequent:
Child Mind Institute is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Child Mind Institute has 4 studies filed under Depression — fewer than ten, so there is no comparison to draw.
300 of the studies in Depression with a site in United States that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05552053Phase 3Cedars-Sinai Medical CenterResources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women | 2026-12-31 |
| NCT06922110Phase 3Xenon Pharmaceuticals Inc.An Open-Label Study of Azetukalner in Major Depressive Disorder | 2027-01 |
| NCT05474846Phase 3M.D. Anderson Cancer CenterCombination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer | 2027-02-28 |
| NCT04777357Phase 3AbbVieA Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. | 2027-03 |
| NCT07076407Phase 3Xenon Pharmaceuticals Inc.A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | 2027-05 |
Add all 300 to your calendar (.ics) → With an account.
Among the 3,715 studies in Depression with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The current project is a pilot study that seeks to compare the efficacy of Brief Behavioral Activation's treatment-as-usual that uses paper and pencil tools to Kandoo, a digital, gamified version of activity scheduling and self-monitoring, in a diverse sample of youth presenting with clinically significant symptoms of depression. We will compare the level of pre- and post-treatment depressive symptoms in participants, who will participate in an 8-week brief behavioral activation treatment protocol augmented with Kandoo to the pre- and post- treatment depressive symptoms in the control participants, who will participate in 8-week, treatment as usual, brief behavioral activation treatment protocol. To explore treatment response for the clinically significant symptoms, we will obtain pre- and post-treatment measures of depression, global functioning, and patient goals. During the standard clinical intake, additional information will be obtained, including detailed demographics, medical history, mental health status, and social skills. Beyond determining the overall effectiveness of BBA augmented with Kandoo, the sample diversity and availability of clinical behavioral observations of the participants will permit the development of explanatory models of predictive factors for BBA with Kandoo intervention outcomes.
Youth depression is one of the most common psychiatric conditions, affecting 1%-3% of prepubertal children and 3%-9% of adolescents. By late adolescence, between 20-25% of youth will have experienced at least one episode of major depression. Conservative prevalence estimates suggest that in a single year, between 12.5% of 12- to 17-year-olds experience symptoms of a major depressive episode5. Accordingly, pediatric mood disorders, including but not limited to major depressive disorder, are a major public health concern. These issues are serious and potentially lethal. In 15 year follow-up research of children with major depression, 4% died by suicide. In 10- to 15-year follow-up research of adolescents with depression, 8% died by suicide1. Individuals who experience depressive episodes in adolescence are at increased risk for at least one recurrent episode in adulthood. Moreover, youth depression is related to a range of additional poor psychiatric, as well as medical outcomes, such as increased risk of suicidality, higher risk for comorbid psychiatric conditions (e.g., anxiety, substance use, etc.), increased risk of obesity, type 2 diabetes, etc.
Adolescence is a pivotal developmental period that is characterized by the understanding and building of relationships, exploration of interests, development of essential skills needed for adaptive living and professional success, and the transition to higher education and/or the workforce. Depression interferes with these processes and has long-term impact on socioeconomic status, as well as a myriad of psychosocial outcomes: relationship challenges (e.g., familial, peer, romantic, etc.), less perceived social support, lower academic achievement, and attainment, and unemployment2. Even after spontaneous remission or a successful course of treatment, given depressive sequelae (i.e., underdeveloped coping skills, dysfunctional thinking patterns, cognitive distortions, impaired interpersonal relationships, etc.), individuals often require long-term treatment1. Even though treatment for depression is largely effective and untreated depression is associated with more severe prognostic consequences, most individuals with depression do not receive treatment3.
Only about one-third of youth exhibiting clinical psychiatric and behavioral issues access professional care. Low treatment utilization is associated with systematic difficulties (e.g., cost, waitlists, etc.), perceptions towards care providers and the treatment process, issues with the recognition and understanding of psychiatric conditions and related treatment, and characteristics of family systems. Key access to care challenges includes high demands for specialists' services and extensive waitlists5. Decreasing obstacles and increasing facilitators are critical to facilitating youths' access to much needed clinical services. In addition, youth report a range of their own perceptions (e.g., embarrassment, previous experiences, negative expectations, preference to be self-reliant, societal stigma, confidentiality concerns, etc.) as factors that impede their help seeking behaviors and psychiatric health.
Behavioral models of depression maintain that symptoms emerge as an individual has decreased positive experiences and increased negative experiences. As this pattern repeats, activity levels decrease and low mood intensifies, initiating the 'vicious cycle' of depression. Brief Behavioral activation (BBA) has three aims, which are accomplished through activity scheduling and self-monitoring. The first aim is to decrease non-adaptive behaviors, such as avoidance, that maintain depressive symptoms. The second aim is to increase valued, adaptive activities that decrease depressive symptoms. The third aim is problem solving focused on any obstacles and impediments to completing valued adaptive activities. By increasing participation in preferred and rewarding activities, BBA breaks the aforementioned vicious cycle. As participation in preferred and valued activities increases, the individual is reinforced, leading to decreased depressive symptoms. Research demonstrates that BBA is clinically effective at decreasing depressive symptoms in adults and adolescents. The treatment has outcomes consistent with other established depression treatments (e.g., cognitive behavioral therapy, interpersonal therapy, etc.)12.
An essential component of BBA is "homework," which involves participating in an engaging, pleasurable activity, as well as pre- and post-assignment mood tracking. Despite this positive relationship between homework adherence and treatment outcomes, homework completion is consistently low. For youth, although highly variable, completion rates are approximately 50%; this often declines as the treatment sessions progress. Although between session tasks are formulated with the goal of completion, adherence is dependent on the patient's willingness and capacity to independently accomplish the activity. Many factors interfere with independent completion of homework: lack of real time clinician encouragement, live feedback, and support for troubleshooting. Youth report that they value homework and know that it is important for treatment success; however, they concurrently indicate that they do not complete tasks because of low motivation, no interest, lack of support, as well as the perception that the assignments are time consuming. With increased support, such as through an engaging, digital, game-like format, assignment adherence may improve13.
Adolescent mental health is recognized as a highly concerning global health issue. When clinically significant psychiatric symptoms emerge during adolescence, if promptly and effectively treated, the issues are decreased or eliminated prior to adulthood. However, when treatment is not provided, problems persist and/or exacerbate, chronic mental distress is instigated, risk increases for challenges related to academic, professional, economic, social, interpersonal, and adaptive functioning. Efficiently and effectively addressing youth mental health challenges with practical and effective treatments is critically needed. Various initiatives are focused on addressing the increasing prevalence of psychiatric conditions in youth, as well as the challenges associated with accessing effective treatment. The saturation of digital devices and platforms has created opportunities to provide digital therapeutics. As part of its work with the Children and Youth Behavioral Health Initiative (CYBHI), the Child Mind Institute (CMI) has launched an ambitious program to tackle the behavioral health symptoms that impact youth and their families. CMI is strongly focused on improving youth mental health services through the development of next-generation digital therapeutics. CMI has conducted decades of scientific research on pediatric behavioral health challenges based on this work. CMI believes these products have the potential to provide low-cost solutions for conditions such as depression and anxiety. One of the components of the collaboration between CYBHI and CMI is Kandoo, a geolocation-based gaming product intended to help youth develop healthy habits by gamifying components of Brief Behavioral Activation. Although Brief Behavioral Activation is a well-documented, evidence-based, therapeutic avenue, it is still unclear how supplementing the treatment with a digital product will help children and teens in clinical practice. To continue developing Kandoo, CMI wants to better understand the lived experiences of youth, including their existing gaming behaviors.
Significance We have evidence-based treatments for depression, but these are limited by access to services and adherence to the treatments when they can be initiated. By increasing adherence, we can be more efficient in providing services, and the increased efficiency will not only improve outcomes but also save clinician time which can be deployed for the care of more adolescents. Kandoo, a smartphone app, is designed to augment BBA by increasing engagement, adherence, and efficiency of the "homework" component of BBA.
Kandoo may increase treatment efficiency and efficacy for youth with symptoms of adolescent depression. Kandoo uses tablets and smartphones, to digitally deliver the components of brief behavioral activation that are traditionally deployed in a paper/pencil format. Kandoo delivers therapeutic content to individuals in situ (e.g., at school or home) in support of treatment provided directly by clinicians, in-person or remotely. Over the past decade, there has been an explosion of digital mental health products; however, research on the effectiveness of these programs has been limited and less than encouraging. From a resource perspective, supplementing services via a digital app is ideal, as it removes some of the dependencies on the clinic and therapist, as well as resources, such as transportation, which can vary substantially. In addition, it removes the burden of self-monitoring and tracking and, by providing immediately updated information about treatment progress, engaging psychoeducation content, and motivating gamified designs. Digital tools are expected to increase the user's level of treatment engagement and positively impact treatment outcomes. Kandoo was designed to meet these demands, while collecting data on treatment progress and patient status, as well as serving as a screening tool for those who may need additional support.
Gamification has the potential to increase sustained engagement and adherence with interventions. Sustaining engagement is a key challenge for the delivery of treatments, especially when working with depressed youth who are expected to complete homework assignments and otherwise function independently in unstructured or unsupervised settings (e.g., the home). Gamification is a commonly cited means of improving and sustaining engagement, as it can increase motivation through the creation of a positive, reward-driven learning environment that easily and immediately provides feedback3,4. Appealing graphics and other media-based features (e.g., engaging digital psychoeducational content, in-app rewards) are added benefits of gamification; together these features serve to increase motivation for treatment and support and sustain at-home interventions8.
Study Design:
Evaluate the effectiveness of Behavioral Activation, augmented with Kandoo, in a sample of youth with depressive symptoms.
This study will enroll patients receiving BBA from the Child Mind Institute Medical Practice and Forth Health (https://www.forthealth.com/). Fort Health is a virtual mental healthcare service that was built in collaboration with the Child Mind Institute. Fort Health has been designed for children and adolescents, between 4 and 24 years of age. Through online platforms, Fort Health provides accessible, and evidence-based care, including online therapy, parent coaching, and psychiatry services. To ensure coordinated care, therapy, coaching, and psychiatry services are integrated with each other, as well as with the care given by primary care providers. Services are offered in New York, New Jersey, and Pennsylvania, and Illinois and Texas will be added soon. CMI will contract with Fort Health to identify eligible patients in their practice, introduce the study, and conduct BBA therapy. This study will enroll 2 groups:
Group 1 (CMI): This group uses a pre-post-treatment trial design of BBA augmented with Kandoo in 50 youth (males and females, ages 13.0-25.11). We will recruit participants already enrolled in the Child Mind Institute's (CMI) outpatient clinic, which offers treatment to youth with mental health and learning disorders. All participants in this group will receive BBA augmented with Kandoo.
Group 2 (Fort Health): This group uses a control group pre-post-treatment trial design of BBA augmented with Kandoo in 200 youth (males and females, ages 13.0-25.11). CMI will partner with Fort Health to recruit patients for group 2. We will recruit participants already enrolled in Fort Health's Virtual Mental Health clinic, which offers treatment to youth with mental health and learning disorders. Participants in this group will be randomized into either the BBA treatment as usual group (control group) or the BBA augmented with Kandoo group (Kandoo treatment group). One hundred participants will be randomly assigned into each group.
For both groups, clinicians will be informed of the study and will be asked to refer patients who have depressive symptoms and are candidates for BBA therapy. It is expected that the clinical presentation will include depressive symptoms consistent with mild-to-moderate depression. Two of the symptoms are (1) depressed/irritable mood most of the day and (2) markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day.
The standard BBA treatment protocol includes 8 weekly sessions. Study participants and their clinicians are allowed up to 16 weeks to complete the treatment, allowing for typical and expected reasons for missed sessions (e.g., vacation, illness, scheduling difficulties, etc.). Non-study related interventions will be permitted during the course of the study, consistent with standard practice. These situations will be documented. Participants' symptoms will be assessed weekly using the Mood and Feelings Questionnaire (MFQ). Fifty youth will be recruited to the BA + Kandoo Treatment study. The study will use a pre-post study design.
Variables of interest will be measured before, throughout, and at the end of the treatment. A battery of questionnaires examining depression, global functioning, patient goals, in-therapy feedback, and attitudes towards the digital platform will be administered. At sessions 1, 5, and 8, depression, global functioning, and goals measures will be administered. At sessions 2, 3, 4, 6, and 7, the abbreviated depression measure will be administered. In addition, 6 weeks after session 8, the depression measure will be re-administered as extended post-treatment monitoring. Please see Appendix A for a detailed list of the measures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Current exclusionary psychiatric conditions are (not others):
Participants will use Kandoo to track their activities while receiving Brief Behavioral Activation treatment.
Device: Kandoo
Participants will use paper and pencil worksheets to track their activities while receiving Brief Behavioral Activation treatment.
Kandoo is an app that allows patients to track their activities in an engaging and gamified platform.
Depressive Symptoms and Global Functioning
We will compare the pre- and post-treatment depressive symptoms and global functioning of participants, who completed BBA with Kandoo.
Time frame: 8 weeks
Improvement Factors
We will explore what factors influenced improved as a result of BBA treatment with Kandoo, including explanatory models of predictive factors for BBA with Kandoo intervention outcomes.
Time frame: 8 weeks
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Mar 2025; primary completion for Aug 2025, 5 months later.
Of 3,479 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 5 months is below that.
Counting every sponsor, half of 3,577 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Child Mind Institute